Jaguar health hosts symposium on the management of cancer therapy-related diarrhea

Jaguar health subsidiary napo pharmaceuticals' ontarget trial adding international sites, targeting completion of enrollment in q2 2023 san francisco, ca / accesswire / november 21, 2022 / jaguar health, inc. (nasdaq:jagx) and its wholly owned subsidiary napo pharmaceuticals (napo) today announced that napo hosted a hybrid symposium on november 18, 2022 titled management of cancer therapy-related diarrhea: is it time for a paradigm shift? the symposium featured presentations by leading oncology and infectious disease experts and discussed the impact of cancer therapy-related diarrhea (ctd) as well as the unmet need of ctd burden based on current management guidelines.
JAGX Ratings Summary
JAGX Quant Ranking